Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Impel Pharmaceuticals Inc (IMPL)

Impel Pharmaceuticals Inc (IMPL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
Cellarity Strengthens Executive Leadership Team Business Wire - Tue Apr 11, 2023

Cellarity , a life sciences company founded by Flagship Pioneering to transform the way medicines are discovered, announced today the appointments of John Leaman, M.D., M.B.A., as Chief Financial Officer...

IMPL : 0.0400 (-27.27%)
SELB : 0.8812 (-8.00%)
MDGN : 5.57 (+3.15%)
DNLI : 17.48 (+3.99%)
EVLO : 0.0495 (+4.21%)
FHTX : 6.52 (+6.63%)
MRNA : 123.70 (-1.50%)
OMGA : 2.74 (-0.72%)
SANA : 10.36 (+5.93%)
MCRB : 1.1300 (+1.80%)
Impel Pharmaceuticals Inc. (IMPL) Reports Q4 Loss, Tops Revenue Estimates Zacks - Fri Mar 24, 2023

Impel Pharmaceuticals Inc. (IMPL) delivered earnings and revenue surprises of 6.73% and 23.35%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?...

IMPL : 0.0400 (-27.27%)
INFI : 0.0080 (-50.00%)
Century Therapeutics, Inc. (IPSC) Reports Q4 Loss, Misses Revenue Estimates Zacks - Thu Mar 16, 2023

Century Therapeutics, Inc. (IPSC) delivered earnings and revenue surprises of 8.33% and 81.41%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?...

IPSC : 3.18 (+6.00%)
IMPL : 0.0400 (-27.27%)
Assertio (ASRT) Tops Q4 Earnings and Revenue Estimates Zacks - Wed Mar 8, 2023

Assertio (ASRT) delivered earnings and revenue surprises of 482.61% and 1.58%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

ASRT : 1.0000 (-0.99%)
IMPL : 0.0400 (-27.27%)
Rigel Pharmaceuticals (RIGL) Q4 Earnings and Revenues Surpass Estimates Zacks - Tue Mar 7, 2023

Rigel (RIGL) delivered earnings and revenue surprises of 114.29% and 36.56%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

RIGL : 1.2000 (+4.35%)
IMPL : 0.0400 (-27.27%)
Ocular Therapeutix (OCUL) Moves 35.1% Higher: Will This Strength Last? Zacks - Tue Feb 14, 2023

Ocular Therapeutix (OCUL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase...

OCUL : 6.19 (+5.45%)
IMPL : 0.0400 (-27.27%)
Impel Pharmaceuticals Inc. (IMPL) Reports Q3 Loss, Lags Revenue Estimates Zacks - Mon Nov 14, 2022

Impel Pharmaceuticals Inc. (IMPL) delivered earnings and revenue surprises of -50.57% and 40.27%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the...

IMPL : 0.0400 (-27.27%)
VVOS : 2.60 (-1.10%)
ProPhase Labs, Inc. (PRPH) Q3 Earnings Miss Estimates Zacks - Thu Nov 10, 2022

ProPhase Labs, Inc. (PRPH) delivered earnings and revenue surprises of -60% and 28.38%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

PRPH : 5.41 (+1.86%)
IMPL : 0.0400 (-27.27%)
Sage Therapeutics, Inc. (SAGE) Reports Q3 Loss, Tops Revenue Estimates Zacks - Tue Nov 8, 2022

Sage Therapeutics, Inc. (SAGE) delivered earnings and revenue surprises of -6.94% and 3.70%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?...

SAGE : 13.59 (+3.74%)
IMPL : 0.0400 (-27.27%)
FibroGen (FGEN) Reports Q3 Loss, Misses Revenue Estimates Zacks - Mon Nov 7, 2022

FibroGen (FGEN) delivered earnings and revenue surprises of -18.07% and 53.74%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

FGEN : 1.1300 (-0.09%)
IMPL : 0.0400 (-27.27%)

Barchart Exclusives

Bitcoin Stalls- Are Higher Highs on the Horizon? Barchart - 3 minutes ago
Bitcoin has only ventured under the $60,000 per token level a few times since early March, as the price consolidated after making a new record peak. Bitcoin is the leading cryptocurrency, and the spot Bitcoin ETFs have increased its profile, leading to a new all-time high. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot